Alpha 2.0
Login Register
» Authors » Seiichi Kobayashi

Seiichi Kobayashi

Explore the profile of Seiichi Kobayashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 92
Citations 1584
Followers 0
Related Specialties
General Medicine
Pharmacology
Pulmonary Medicine
Top 10 Co-Authors
Masaru Yanai
Hiroshi Kubo
Masakazu Hanagama
Mitsuhiro Yamada
Masatsugu Ishida
Ken-Ichi Hirata
Nobutaka Inoue
Mitsuhiro Yokoyama
Seinosuke Kawashima
Satoshi Suzuki
Published In
Respir Investig
J Arrhythm
Nihon Naika Gakkai Zasshi
Intern Med
Thorax
Affiliations
Soon will be listed here.
Recent Articles
1.
The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases
Ono M, Kobayashi S, Masakazu H, Ishida M, Sato H, Okutomo K, et al.
Medicine (Baltimore) . 2024 Jul; 103(28):e38920. PMID: 38996147
Methods: 39 patients with IPF or other progressive fibrosing ILDs who started nintedanib at a regular dose (300 mg/day) were enrolled. We compared the characteristics between patients who stopped nintedanib...
2.
Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020-2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society
Kamata H, Takamatsu K, Fukunaga K, Chubachi S, Nakagawara K, Namkoong H, et al.
Respir Investig . 2024 Apr; 62(4):572-579. PMID: 38669898
Background: No comprehensive analysis of the pulmonary sequelae of coronavirus disease 2019 (COVID-19) in Japan based on respiratory function tests and chest computed tomography (CT) has been reported. We evaluated...
3.
Four-year mortality and physical activity in Japanese patients with chronic obstructive pulmonary disease
Kobayashi S, Chiba F, Ishida M, Satoh H, Ono M, Hanagama M, et al.
Respir Investig . 2024 Apr; 62(4):538-540. PMID: 38643535
Background: Physical activity (PA) is associated with the risk of mortality in patients with chronic obstructive pulmonary disease (COPD); however, evidence is limited to the Japanese population. This study aimed...
4.
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19
Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, et al.
Sci Rep . 2024 Jan; 14(1):165. PMID: 38168544
An inhibitor of plasminogen activator inhibitor (PAI)-1, TM5614, inhibited thrombosis, inflammation, and fibrosis in several experimental mouse models. To evaluate the efficacy and safety of TM5614 in human COVID-19 pneumonia,...
5.
Physical activity and outcomes in Japanese patients with chronic obstructive pulmonary disease: From the Ishinomaki COPD Network registry
Kobayashi S, Chiba F, Ishida M, Satoh H, Ono M, Hanagama M, et al.
Respir Investig . 2023 Dec; 62(1):107-112. PMID: 38101277
Background: Low physical activity levels are associated with an increased risk of exacerbations and all-cause mortality in patients with chronic obstructive pulmonary disease (COPD); however, evidence is limited in a...
6.
Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial
Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, et al.
J Infect Chemother . 2023 Jul; 29(11):1054-1060. PMID: 37507087
We previously reported the finding of symptom relief in a randomized controlled trial with the combined use of kakkonto and shosaikotokakikyosekko added to conventional treatment in patients with coronavirus disease...
7.
Multiple cavitary lung lesions from colorectal cancer responding to chemotherapy
Saito T, Kobayashi S, Okutomo K, Miura T, Ohori H, Yanai M
Respir Med Case Rep . 2023 May; 44:101865. PMID: 37214592
Lung metastasis is an uncommon cause of multiple cavitary lung lesions. Herein, we report a case of multiple cavitary lung lesions of colorectal cancer that responded to chemotherapy. An 81-year-old...
8.
Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients
Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, et al.
Front Pharmacol . 2022 Nov; 13:1008946. PMID: 36438822
The traditional Japanese (Kampo) medicine, kakkonto with shosaikotokakikyosekko, has antiviral and anti-inflammatory effects. In this randomized trial, patients with mild and moderate coronavirus disease (COVID-19) were randomly allocated to the...
9.
Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI Study-observation)
Takayama S, Yoshino T, Koizumi S, Irie Y, Suzuki T, Fujii S, et al.
Intern Med . 2022 Nov; 62(2):187-199. PMID: 36328579
Objective Patients in whom coronavirus disease 2019 (COVID-19) was suspected or confirmed between January 1, 2020, and October 31, 2021, were enrolled from Japanese hospitals in this multicenter, retrospective, observational...
10.
A case of metastatic endobronchial tumor from uterine leiomyosarcoma
Ono M, Kobayashi S, Hanagama M, Ishida M, Sato H, Okutomo K, et al.
Respir Med Case Rep . 2022 Oct; 40:101747. PMID: 36193341
A 54-year-old woman presented with persistent productive cough, found to have an endobronchial tumor which obstructed the left upper lobe bronchus. Histopathological examination of a transbronchial biopsy of the endobronchial...